This Project Grant award from the National Institutes of Health's National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) provides $406,500 to Directseq Biosciences, Inc. to advance their next-generation mass spectrometry-based sequencing (NGMS-SEQ) methods for high-throughput direct sequencing and quantitative mapping of RNA modifications. The key objectives are to: 1) enhance NGMS-SEQ techniques to enable direct sequencing of various tRNA samples, including...
This Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172) provides $215,088 to Directseq Biosciences, Inc. to develop and test an "Exhaustive De Novo Sequencing of Every RNA in a Sample by a Layer-by-Layer Mass Spectrometry Ladder Intensity Approach." The project aims to create a comprehensive RNA sequencing and modification profiling method that can identify and sequence all RNA species in a sample...
The National Institute of General Medical Sciences (NIGMS) awarded a $305,892 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to Dotquant LLC, a for-profit biotechnology research and development company, to develop a new in vitro transcription kit for high-yield synthesis of chemically modified RNA. This innovation aims to drastically improve the affordability of current and future RNA drugs by combining the benefits of wild-type T7 RNA polymerase's high efficiency and...
This Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research Federal Grant Program (CFDA 93.172) aims to develop an enzymatic system for site-specific incorporation of modified RNA bases. The $2,040,824 award, effective July 1, 2024 through April 30, 2027, will enable the University of Massachusetts to build on recent advances in co-immobilized flow transcription. The proposed research seeks to generate RNA molecules with strategically placed...
This Project Grant award of $594,501.00 from the National Human Genome Research Institute (NHGRI), under the Human Genome Research federal grant program (CFDA 93.172), supports the development of a unified probabilistic model and software implementation for analyzing nascent RNA sequencing data. The primary objectives are to: Develop statistical tests and machine learning methods for differential analysis of transcription-associated rates from nascent RNA sequencing data. Create a statistical...
This Project Grant award from the National Institutes of Health's National Human Genome Research Institute provided $768,678 to Molecular Assemblies, Inc. to develop a fully enzymatic oligonucleotide synthesis cycle using engineered template-independent polymerases and a novel phosphate dNTP blocking group. The award supports the goals of the Human Genome Research program (CFDA 93.172) to accelerate genome research and its application to human health. Specifically, the awardee will engineer...
This Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $204,688.00 in funding to The Johns Hopkins University to develop innovative sequencing technologies to investigate DNA ADP-ribosylation, an under-studied DNA modification implicated in critical biological processes. The research program aims to create two complementary techniques - one using high-throughput Illumina...
The National Human Genome Research Institute (NHGRI) awarded a $409,699 Project Grant (CFDA 93.172 - Human Genome Research) to the Regents of the University of Michigan. The grant, effective July 1, 2024 through April 30, 2027, will fund the development of integrated liquid chromatography-mass spectrometry (LC-MS/MS) and nanopore sequencing methods to enable direct and quantitative detection of RNA modifications. The University of Michigan is collaborating with researchers at the University of...
The Alida Biosciences Inc. was awarded a $765,105 Project Grant from the National Institutes of Health National Human Genome Research Institute under the Human Genome Research federal grant program (CFDA 93.172) on August 17, 2021 to complete work by February 28, 2022. The grant funds the development of a new approach to analyze RNA modifications across entire transcriptomes in a multiplexed reaction at near single-base resolution. Currently available methods either lack sequence context or...
This $3,000,000 project grant, awarded by the National Science Foundation (NSF) under the Engineering (CFDA 47.041) program, aims to solve the long-standing challenge of developing self-amplifying ribonucleic acid (SARNA) technologies. The project, led by Trustees of Boston University, a private non-profit research university, will: Synthesize a diverse library of modified nucleoside triphosphates (ModNTPs) and use them to produce modified SARNA with extended cellular half-life. Evaluate the...
TWICE READING OF RNA BY DIRECT NANOPORE SEQUENCING - PROJECT SUMMARY HUMAN TRANSCRIPTOMES ARE ENDOWED WITH MANY INTRIGUING RNA MODIFICATIONS THAT ARE DYNAMIC AND REVERSIBLE. MANY OF THESE MODIFICATIONS REGULATE GENE EXPRESSION AND CELL-FATE DECISION, WHILE EMERGING NEW FUNCTIONS ARE ALSO LIKELY TO IMPACT HUMAN HEALTH AND DISEASE. HOWEVER, PRECISE MAPPING AND QUANTIFYING MODIFICATIONS REMAINS A CHALLENGE. WHILE THE OXFORD NANOPORE TECHNOLOGIES (ONT) PLATFORM OF DIRECT RNA SEQUENCING CAN DETECT RNA MODIFICATIONS AS BASECALL ERRORS, A MAJOR WEAKNESS IS THE LACK OF QUANTIFICATION OF THESE ERRORS AND THE INCREASED ERRORS NEAR THE SITE OF A MODIFICATION. WE HYPOTHESIZE THAT USING 3DPOL, THE RNA-DEPENDENT RNA POLYMERASE (RDRP) OF POLIOVIRUS, TO COPY EACH RNA PROVIDES A MECHANISM OF "TWICE READING" OF THE RNA TO IMPROVE ACCURACY. IN THIS TWICE-READING MECHANISM, 3DPOL CAPTURES THE FLEXIBLE FOLD-BACK OF THE 3'-END OF AN RNA AS THE PRIMER FOR REPLICATION, PRODUCING A DOUBLE-STRANDED (DS)-HAIRPIN HELIX THAT PHYSICALLY LINKS THE TEMPLATE STRAND WITH THE COPIED STRAND. THIS PHYSICAL LINK IS IMPORTANT, ALLOWING EACH RNA MODIFICATION TO HAVE TWO READS, FIRST THROUGH NANOPORE SEQUENCING OF THE COPIED STRAND AND THEN THE TEMPLATE STRAND, SUCH THAT THE TWO READS ARE RELATABLE. BECAUSE THE READ IN THE COPIED PORTION IS PRODUCED BY THE HIGH-FIDELITY 3DPOL, IT PROVIDES THE "GROUND TRUTH" FOR THE READ IN THE TEMPLATE PORTION. IN AIM 1, WE WILL DETERMINE HOW 3DPOL COPIES AN RNA MODIFICATION BY DEFINING ITS FIDELITY AND SIGNATURE OF NUCLEOTIDE INCORPORATION. THIS IS TO DETERMINE HOW THE TWO READS ARE RELATED TO EACH OTHER. USING A SYNTHETIC RNA TEMPLATE, WE WILL MEASURE THE FIDELITY AND THE SIGNATURE OF 3DPOL READOUT FOR ABUNDANT MODIFICATIONS IN HUMAN MRNAS. WE WILL PERFORM THE SAME ANALYSIS FOR PROCESSIVE REVERSE TRANSCRIPTASES (RTS) TO DISCERN THE DIFFERENCES BETWEEN RNA- AND CDNA-REPLICATION OF AN RNA. WE WILL ALSO GENERATE 3DPOL VARIANTS WITH A DIFFERENT NUCLEOTIDE-INCORPORATION SIGNATURE THAN THE NATIVE ENZYME, WHICH WILL PROVIDE VALUABLE NEW TOOLS FOR QUANTIFYING RNA MODIFICATIONS. IN AIM 2, WE WILL DETERMINE THE ELONGATION VELOCITY OF 3DPOL IN END-TO-END READING OF LONG RNAS. THIS IS TO ASSESS THE PROCESSIVITY OF 3DPOL UPON ENCOUNTERING CHALLENGING SEQUENCES AND DIVERSE STRUCTURES TYPICAL OF CELLULAR RNAS. WE WILL USE A LONG NON- CODING RNA TO MEASURE POSITION-DEPENDENT VELOCITY ACROSS THE TEMPLATE. WE WILL COMPARE THE VELOCITY OF 3DPOL TO PROCESSIVE RTS TO PROVIDE NEW INSIGHT INTO THE STRENGTHS AND WEAKNESSES OF EACH ENZYME. IN AIM 3, WE WILL GENERATE SYNTHETIC RNA STANDARDS, EACH WITH A SITE-SPECIFIC MODIFICATION (Ps, M6A, OR M5C) FOR MACHINE LEARNING AND ALGORITHM DEVELOPMENT. WE WILL ALSO GENERATE A CONTROL LIBRARY OF LONG RNAS, EACH WITH A MODIFICATION, AND DETERMINE THE IMPROVED ACCURACY FROM 1-READ TO 2-READ AND EVEN TO MULTIPLE READS UPON 3DPOL REPLICATION OF THE LIBRARY. WE WILL THEN DETERMINE THE IMPROVED ACCURACY UPON 3DPOL REPLICATION OF A HUMAN TRANSCRIPTOME. THE DELIVERABLE IS A NANOPORE KIT CONSISTING OF REAGENTS FOR DETECTING AN RNA MODIFICATION IN TWICE READING OF TRANSCRIPTOMES IN A NEW STRATEGY THAT WILL SIGNIFICANTLY IMPROVE READ ACCURACY FOR RESEARCH IN ALL BIOLOGICAL AREAS.